Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.03 +1.37 (+0.89%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets. 
Via InvestorPlace
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
J&J Moves Closer to Resolving Baby Powder Lawsuits, 75% of Plaintiffs Support $6.5B Settlement
Johnson & Johnson secures over 75% support for a $6.5 billion settlement plan to resolve thousands of lawsuits over claims that its talc-based baby powder caused cancer. The company faces ongoing legal... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Buy on the Dip: August 2024
These blue-chip stocks are well-positioned to provide positive returns to investors due to their high growth potential. 
Via InvestorPlace
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Medicare beneficiaries face higher costs for Johnson & Johnson's Stelara due to a shift in coverage from Part B to Part D. The OIG report shows a nearly tenfold increase in Medicare spending on... 
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Why the dividend investor may take a look at JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in August
These longtime winners still have a lot to offer. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy and Hold Forever
Dividends remain one of the best long-term avenues to generating wealth. Here are three stocks you can buy and hold forever. 
Via The Motley Fool
Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market
Five exceptionally safe, time-tested stocks have the necessary tools to make their shareholders richer. 
Via The Motley Fool
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Explore the best dividend payouts from leading companies for sustainable, steady and growing income streams. 
Via InvestorPlace
A Closer Look at 14 Analyst Recommendations For Johnson & Johnson
Via Benzinga
3 Dividend Growth Stocks to Buy Hand Over Fist in August
There are blue-chip bargains paying large and growing dividends in the healthcare space. 
Via The Motley Fool
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
These three dividend growth stocks are among the best options for long-term investors seeking reliable total returns in this current market. 
Via InvestorPlace
The Market's Excessive Recession Fears
Today's Research Daily features a comment on updated research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, Inc., and Marsh & McLennan Companies, Inc., as well as a micro-cap... 
Via Talk Markets
Topics Economy
Exposures Economy
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
3 Defensive Stocks Weathering the Market Storm
Despite last week's market downturn, JNJ, KO, and PG posted gains, demonstrating resilience and potentially serving as defensive safe-haven investments. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
The S&P 500 Had Its Worst July in a Decade. Should You Really Buy Stocks Now?
It's key to take a long-term view. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
These two healthcare companies have far more upside potential than Johnson & Johnson. 
Via The Motley Fool
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Abbott Laboratories' growth rate may look comparable to Johnson & Johnson's, but in the long run it could become much higher. 
Via The Motley Fool
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
7 Leading MedTech Stocks for Next-Gen Health Solutions
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Q3’s Rising Stars: 3 Dow Stocks for Your Must-Watch List
These Dow stocks to watch have all been beaten down over the past year or more but are now poised for a rebound. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July. 
Via MarketBeat
Topics ETFs
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.